Humankind Investments LLC reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 31.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,252 shares of the biopharmaceutical company’s stock after selling 8,695 shares during the period. Bristol-Myers Squibb makes up about 0.5% of Humankind Investments LLC’s holdings, making the stock its 28th largest position. Humankind Investments LLC’s holdings in Bristol-Myers Squibb were worth $1,231,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Dakota Wealth Management acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $332,000. Covestor Ltd increased its stake in Bristol-Myers Squibb by 111.5% in the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,082 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Bristol-Myers Squibb by 53.2% during the first quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after purchasing an additional 57,444 shares during the last quarter. Ergoteles LLC acquired a new stake in Bristol-Myers Squibb in the first quarter valued at $1,997,000. Finally, Mackenzie Financial Corp increased its position in shares of Bristol-Myers Squibb by 25.1% in the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock valued at $24,725,000 after buying an additional 68,018 shares in the last quarter. 74.98% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Trading Up 1.5 %
BMY stock traded up $0.75 on Tuesday, hitting $50.90. 2,890,221 shares of the company were exchanged, compared to its average volume of 9,577,996. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.18 and a quick ratio of 1.07. The stock has a market capitalization of $103.57 billion, a price-to-earnings ratio of 12.73, a price-to-earnings-growth ratio of 1.59 and a beta of 0.38. Bristol-Myers Squibb has a twelve month low of $49.49 and a twelve month high of $81.43. The business’s fifty day moving average is $56.34 and its two-hundred day moving average is $61.32.
Bristol-Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 4.48%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 57.87%.
Insider Transactions at Bristol-Myers Squibb
In related news, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.08% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently commented on BMY. TheStreet cut shares of Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research note on Thursday. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 27th. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, October 9th. The Goldman Sachs Group lowered their target price on Bristol-Myers Squibb from $81.00 to $69.00 and set a “buy” rating on the stock in a report on Monday, October 30th. Finally, Wells Fargo & Company cut their price target on Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating for the company in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $64.76.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
- Five stocks we like better than Bristol-Myers Squibb
- Upcoming IPO Stock Lockup Period, Explained
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- ESG Stocks, What Investors Should Know
- TripAdvisor is on AI-powered recovery from record lows
- How to Invest in Artificial Intelligence
- High-yield, low-beta value plays for buy-and-hold investors
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.